Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells

被引：0
|
作者：
Yue-qin Wang
Ai-jun Shen
Jing-ya Sun
Xin Wang
Hong-chun Liu
Min-min Zhang
Dan-qi Chen
Bing Xiong
Jing-kang Shen
Mei-yu Geng
Min Zheng
Jian Ding
机构：
[1] China Pharmaceutical University,Department of New Drug Screening Center
[2] Division of Anti-tumor Pharmacology,Department of Thoracic Surgery
[3] Synthetic Organic and Medicinal Chemistry Laboratory,undefined
[4] State Key Laboratory of Drug Research,undefined
[5] Shanghai Institute of Materia Medica,undefined
[6] Chinese Academy of Sciences,undefined
[7] Shanghai Tongren Hospital,undefined
[8] Shanghai Jiao Tong University School of Medicine,undefined
来源：
Acta Pharmacologica Sinica | 2016年 / 37卷
关键词：
non-small cell lung cancer; gefitinib resistance; Hsp90;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1587 / 1596
页数：9
相关论文
共 50 条
  • [41] Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells
    Chen, J.
    Bi, H.
    Hou, J.
    Zhang, X.
    Zhang, C.
    Yue, L.
    Wen, X.
    Liu, D.
    Shi, H.
    Yuan, J.
    Liu, J.
    Liu, B.
    CELL DEATH & DISEASE, 2013, 4 : e814 - e814
  • [42] TREATMENT WITH TRICHOSTATIN A RESTORES SENSITIVITY TO GEFITINIB AND IMPAIRS CANCER STEM CELLS FEATURES IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER CELLS
    Nurwidya, Fariz
    Takahashi, Fumiyuki
    Hidayat, Moulid
    Wirawan, Aditya
    Baskoro, Hario
    Kato, Motoyasu
    Tajima, Ken
    Andarini, Sita
    Yunus, Faisal
    Takahashi, Kazuhisa
    RESPIROLOGY, 2018, 23 : 64 - 65
  • [43] Gefitinib in non-small cell lung cancer
    Tamura, K
    Fukuoka, M
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) : 985 - 993
  • [44] Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells
    J Chen
    H Bi
    J Hou
    X Zhang
    C Zhang
    L Yue
    X Wen
    D Liu
    H Shi
    J Yuan
    J Liu
    B Liu
    Cell Death & Disease, 2013, 4 : e814 - e814
  • [45] Therapeutic Uses of HSP90 Inhibitors in Non-Small Cell Lung Carcinoma (NSCLC)
    Akram, Anam
    Khalil, Sara
    Halim, Sobia Ahsan
    Younas, Hooria
    Iqbal, Sadaf
    Mehar, Saima
    CURRENT DRUG METABOLISM, 2018, 19 (04) : 335 - 341
  • [46] Targeting The Hdac6/hsp90 Axis To Destabilize The Notch1 Receptor In Non-Small Cell Lung Cancer
    Deskin, B.
    Shan, B.
    Lasky, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [47] Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
    Costa, Daniel B.
    Nguyen, Kim-Son H.
    Cho, Young C.
    Sequist, Lecia V.
    Jackman, David M.
    Riely, GregoryJ.
    Yeap, Beow Y.
    Halmos, Balazs
    Kim, Joo H.
    Jaenne, Pasi A.
    Huberman, Mark S.
    Pao, William
    Tenen, Daniel G.
    Kobayashi, Susumu
    CLINICAL CANCER RESEARCH, 2008, 14 (21) : 7060 - 7067
  • [48] Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer
    Loong, Herbert H.
    Kwan, Sui-chun Sampson
    Mok, Tony Shu-kam
    Lau, Yat-ming
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (11)
  • [49] Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer
    Herbert H. Loong
    Sui-chun Sampson Kwan
    Tony Shu-kam Mok
    Yat-ming Lau
    Current Treatment Options in Oncology, 2018, 19
  • [50] Bone Metastasis in EGFR Mutant Non-Small Cell Lung Cancer
    Huang, Shu-Mei
    Yang, Jin-Ji
    Huang, Yi-Sheng
    Chen, Hua-Jun
    Bai, Xiao-Yan
    Zhou, Qing
    Tu, Han-Yan
    Wu, Yi-Long
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S766 - S767
12345